1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,770 | 1,780 | 08:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 04.06. | Dividendenbekanntmachungen (04.06.2026) | 14.021 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| 29.05. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | - | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): RESIGNATION OF AN EXECUTIVE DIRECTOR; CHANGE OF THE CHAIRMAN; AND CHANGE OF COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 29.05. | HAOHAI BIOTEC (06826): POLL RESULTS OF AGM, A SHAREHOLDERS' CLASS MEETING AND H SHAREHOLDERS' CLASS MEETING; 2025 PROFIT DISTRIBUTION; CHANGE OF DIRECTORS ... | - | HKEx | ||
| SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 15.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 06.05. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 30.04. | HAOHAI BIOTEC (06826): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. ANNOUNCEMENT ON THE RECEIPT OF THE "DECISION ... | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 (UPDATED) | 2 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2026 FIRST H SHAREHOLDERS' CLASS MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): FORM OF PROXY FOR THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 29 MAY 2026 | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): NOTICE OF 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 28.04. | HAOHAI BIOTEC (06826): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING AND 2026 FIRST H SHAREHOLDERS' CLASS MEETING | - | HKEx | ||
| 27.04. | HAOHAI BIOTEC (06826): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | - | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF DEPUTY GENERAL MANAGERS | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): 2026 FIRST QUARTERLY REPORT | 1 | HKEx | ||
| 24.04. | HAOHAI BIOTEC (06826): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION ... | 2 | HKEx |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,163 | -2,30 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| AMGEN | 320,00 | +0,52 % | NICE aims to cut funding for Amgen lung cancer drug Lumykras | ||
| STRYKER | 289,90 | +0,38 % | Nach der Rallye: Die UBS nennt neue Börsenfavoriten - und es sind keine KI-Aktien | © Foto: wallstreetonline/KI - OpenAINach der starken Börsenrallye rät die UBS zu defensiven Aktien mit stabilen Geschäften. Warum gerade diese Titel jetzt interessant sein könnten.Nach einem starken... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 581,00 | -0,17 % | Regeneron expects Q2 pre-tax IPR&D charge of ~$127M | ||
| CSL | 74,91 | -0,16 % | CSL shares are up 35% since early June. Is the recovery here to stay? | ||
| BEONE MEDICINES LTD ADR | 266,00 | +1,53 % | BEONE MEDICINES (06160): GRANT OF RESTRICTED SHARE UNITS | ||
| CANSINO BIOLOGICS | 2,500 | -4,58 % | CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America | HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)... ► Artikel lesen | |
| BIOMERIEUX | 68,95 | -0,93 % | Dividendenbekanntmachungen (09.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMEREN CORPORATION US0236081024 0,75 USD 0,6501 EUR AMUNDI SA FR0004125920 - 4,25 EUR BECTON DICKINSON AND COMPANY US0758871091 1... ► Artikel lesen | |
| SINO BIOPHARM | 0,588 | -0,94 % | Astrazeneca lizenziert Atemwegsmedikament von Sino Biopharm ein | DJ Astrazeneca lizenziert Atemwegsmedikament von Sino Biopharm ein
Von Jason Chau
DOW JONES--Astrazeneca hat sich die Rechte an einem Medikament zur Behandlung chronischer Atemwegserkrankungen... ► Artikel lesen | |
| ZAI LAB LTD ADR | 17,100 | -5,00 % | Zai Lab Limited: Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas | Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,617 | +4,58 % | EQS Newswire: CStone Pharmaceuticals: CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights | EQS Newswire / 12/06/2026 / 15:02 UTC+8
Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential... ► Artikel lesen | |
| CASI PHARMACEUTICALS | 0,214 | -4,13 % | Riverty Establishes Bank in Luxembourg | Fintech granted EU CRR banking licence after a 10-month application processRiverty transforms its Payment and Credit business from a PSD2 payment institution into a fully licensed bankBank... ► Artikel lesen | |
| 3SBIO | 2,091 | +3,23 % | 3SBio Inc.: 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone | SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 58,13 | -0,02 % | Tarsus Acquires iRenix Medical To Expand Eye Care Pipeline With Late-Stage IRX-101 | ||
| ARCUTIS BIOTHERAPEUTICS | 27,740 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen |
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,71 % bei einem Aktienkurs von 1,720 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.